“Comparative Efficacy and Safety of Individual SGLT2 Inhibitors (Dapagliflozin, Empagliflozin, and Canagliflozin) on Kidney Function Decline in CKD: A Systematic Review and Network Meta-Analysis”, OAIJMR, vol. 5, no. 6, pp. 1772–1789, Nov. 2025, doi: 10.37275/oaijmr.v5i6.818.